Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 9;27(3):865–876. doi: 10.1158/1078-0432.CCR-20-2385

Figure 6:

Figure 6:

Genes showing significant change in expression (p=<0.05) on exposure to pelareorep in KRAS mutated patients at least in two out of three time points (48 hours, Day8 and Day 15) normalized to pre-pelareorep therapy.

*Genes with signficant change on at least 2/3 time points